Portage Biotech Stocks Surge Over Mesothelioma Drug Results

911 Meso Info

911 Meso Info is a dedicated voice in the fight against mesothelioma, committed to raising awareness, providing reliable information, and empowering individuals affected by this rare disease. With a passion for advocacy, 911 Meso Info delivers insightful resources, up-to-date research, and practical tips to help patients and families navigate their mesothelioma journey. From treatment options and legal guidance to emotional support and prevention strategies, 911 Meso Info is your go-to source for comprehensive mesothelioma knowledge. Connect with us to stay informed and find strength in community. Follow 911 Meso Info for trusted advice and support, and join us in spreading awareness for a brighter tomorrow.

News Summary

Portage Biotech’s stock surged 103.81% after promising preclinical results for PORT-7, a mesothelioma treatment unveiled at ELCC 2025.

Portage Biotech Inc. Stock Soars on Promising Mesothelioma Drug Results

In an astounding turn of events, Portage Biotech Inc. has witnessed its stock skyrocket by 103.81%, hitting an impressive $9.64 in pre-market trading. This surge is largely attributed to promising preclinical results for its cancer treatment candidate, PORT-7, which were unveiled at the 2025 European Lung Cancer Congress (ELCC) held in Paris. This remarkable development has caught the attention of investors and healthcare professionals alike.

Revolutionary Targeting of Mesothelioma

At the heart of this breakthrough is PORT-7, a selective inhibitor targeting the Adenosine A2B receptor. The study, executed by Dr. Luciano Mutti from the Gruppo Italiano Mesotelioma e Oncologia Ambientale, demonstrated that PORT-7 effectively suppressed tumors when used as a standalone treatment. Notably, in a mouse mesothelioma model, the combination of PORT-7 with an anti-PD1 antibody resulted in over 90% tumor growth inhibition, showcasing the potential efficacy of this novel therapeutic approach.

Furthermore, the immunohistochemical analysis conducted as part of the study revealed significant infiltration of immune effector cells, denoted as CD3 and CD45 positive, in the tumors treated with PORT-7. This indicates that the drug may hold the key to overcoming the immune resistance pathways that are characteristic of mesothelioma—a notoriously aggressive cancer with scant treatment options available.

On the Brink of Human Trials

A significant next step for Portage Biotech is the initiation of the first human clinical trial for PORT-7. Alongside this, the company is also making headway with another promising compound, PORT-6, a selective A2A adenosine receptor inhibitor, which is currently in the dose escalation phase. The company has announced plans to co-administer these two compounds in the ADPORT-601 study, marking the first time A2A and A2B antagonists will be combined in human subjects. This dual-inhibitor strategy aims to effectively block adenosine-induced immunosuppression within the tumor microenvironment, potentially enhancing the efficacy of immunotherapy for solid tumors.

Challenges Ahead

Despite these uplifting developments, it is important to recognize the financial challenges that Portage Biotech faces. The company recently reopened patient recruitment in the fourth and final cohort of its Phase 1b ADPORT-601 study for PORT-6, which had been temporarily halted due to financial constraints. This resumption signifies the company’s confidence in the therapeutic potential and safety of PORT-6, although there remains a difficult road ahead.

Currently, Portage Biotech has a market capitalization of $7.65 million and maintains a strong liquidity position with a current ratio of 3.08. However, the stock has experienced a year-to-date decline of 12.19%, marking concerns regarding its overall stability. The company has also been granted an extension by Nasdaq to meet continued listing standards until June 9, 2025, highlighting the pressing need to achieve minimum requirements related to shareholders’ equity, market value, or net income.

Financial Health and Future Outlook

Despite the promising advancements in the realm of cancer therapeutics, Portage Biotech’s financial health score has been rated as ‘Weak’, with a score of 1.49 according to InvestingPro. It is crucial to note that the company has not indicated plans to update forward-looking statements unless legally obligated. As with any emerging biotech firm, while the potential of PORT-7 and its accompanying treatments raises excitement, the journey through clinical trials and market volatility presents substantial challenges that investors and stakeholders alike will watch closely.